Artax raises $10M Series B for autoimmune disease small molecule drug
The funding, led by former Genzyme CEO Henri Termeer, funds the development of an immunomodulator that could be used for multiple sclerosis, type 1 diabetes, psoriasis and other autoimmune disease.